IDXX·IDEXX Laboratories, Inc.
IDXX|Analyst Targets
IDXX|Company Info
IDXX|Insider Trading
IDXX|Fundamentals
IDXX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.70 | - | - |
| Q2'26 | $3.93 | $4.27 | +8.5% |
| Q1'26 | $3.92 | $3.47 | -11.6% |
| Q4'25 | $2.99 | $3.08 | +3.1% |
| Q3'25 | $3.14 | $3.40 | +8.3% |
| Q2'25 | $3.30 | $3.63 | +10.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.2B | - | - |
| Q2'26 | $1.2B | $1.2B | -0.7% |
| Q1'26 | $1.2B | $1.1B | -4.8% |
| Q4'25 | $1.1B | $1.1B | -0.3% |
| Q3'25 | - | $1.1B | - |
| Q2'25 | - | $1.1B | - |
IDXX|Monthly Returns
Market Data
IDXX Stock Snapshot
- Market cap
- 41.28B
- P/E ratio
- 36.2
- Day range
- $514.72 – $528.49
- News sentiment
- 58/100 · Neutral
- Analyst target
- $701.33 (+34.8%)
- Consensus
- Hold · 24 analysts
The chart on IDXX has not stabilised: price is near its 52-week low and the trend is still down. Earnings and guidance carry more weight than macro data at this capitalisation.
Reverse DCF
What growth is priced into IDXX?
At today's price, IDEXX Laboratories, Inc. needs to grow free cash flow about 28.7% a year for the next 10 years to justify its valuation at a 9.74% cost of capital. Over its actual history it has compounded free cash flow at 15.1% a year, so the market is asking for 13.6 percentage points above its own delivered rate. On that basis IDXX looks priced above what its own growth record supports.
- Implied FCF growth
- 28.7%
- Historical FCF CAGR
- 15.1%
- Growth gap
- +13.6 pts
- Verdict
- RICH
- Discount rate (WACC)
- 9.74%
- Beta
- 0.91
Behaviour On Record
What IDXX's own history says about today's numbers
- Realized volatility (21d)
- 21.7% 34th pct
- Below its peak
- -32.1%
- vs 200-day average
- -10.7%
- Up days (1y)
- 49%
IDEXX Laboratories, Inc. is currently running 21.7% annualised volatility over the last 21 sessions. Measured against IDXX's own 13 years of daily returns rather than a market-wide average, that is the 34th percentile — on the quiet side for this stock, against a typical reading of 26.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
IDXX is trading -32.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -24.2%, and the deepest was -48.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -10.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 13th percentile — a narrower gap than it typically runs. Over the past year IDXX closed higher on 49% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, IDXX finished the month higher 8 of 13 times, with a median return of +2.6% and an average of +0.4%. Its strongest month historically has been July at +5.8% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: IDXX has opened more than 2% away from the prior close in 118 of 3,267 sessions (3.6% of the time), with the largest gaps running +5.4% and -9.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, IDXX moved an average of 1.8% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.9% and a largest of +3.2%.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against IDXX's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of IDXX's sector?
IDEXX Laboratories, Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 82
Analyst Rating Changes
Are analysts turning bullish or bearish on IDXX?
Keybanc most recently initiated coverage on IDEXX Laboratories, Inc. to Sector Weight on Oct 12, 2026. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Keybanc — Sector Weight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
IDXX peers & ETF holders
Diagnostics & ResearchMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 9,945,328 | 12.54% | $6.73B | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 8,170,178 | 10.30% | $4.30B | 2026-08-07 |
| Invesco Ltd. | ▲ Buy | 3,611,416 | 4.55% | $1.90B | 2026-08-14 |
| Geode Capital Management, LLC | ▼ Sell | 2,562,886 | 3.23% | $1.35B | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 1,356,103 | 1.71% | $713.91M | 2026-08-13 |
| Northern Trust Corp | ▲ Buy | 918,137 | 1.16% | $483.34M | 2026-08-13 |
| FMR LLC (Fidelity) | ▲ Buy | 822,643 | 1.04% | $433.07M | 2026-08-13 |
| Capital Research Global Investors | ▲ Buy | 789,111 | 0.99% | $415.47M | 2026-08-12 |
| JPMorgan Chase & Co | ▼ Sell | 755,791 | 0.95% | $405.05M | 2026-08-12 |
| Goldman Sachs Group Inc | ▲ Buy | 738,708 | 0.93% | $388.89M | 2026-08-14 |
| Wellington Management Group LLP | ▼ Sell | 726,695 | 0.92% | $382.56M | 2026-08-14 |
| Polen Capital Management LLC | ▼ Sell | 532,384 | 0.67% | $280.27M | 2026-08-04 |
| Bank of America Corp | ▼ Sell | 476,998 | 0.60% | $251.11M | 2026-08-14 |
| Norges Bank | ▼ Sell | 353,944 | 0.45% | $186.33M | 2026-08-12 |
| Baillie Gifford & Co | ▲ New | 353,797 | 0.45% | $186.25M | 2026-08-06 |
| Neuberger Berman Group LLC | ▲ Buy | 353,322 | 0.45% | $186.00M | 2026-08-13 |
| Squarepoint Ops LLC | ▲ Buy | 315,164 | 0.40% | $165.91M | 2026-08-14 |
| William Blair Investment Management, LLC | ▼ Sell | 298,154 | 0.38% | $156.96M | 2026-08-12 |
| Point72 Asset Management, L.P. | ▲ Buy | 262,905 | 0.33% | $138.40M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 209,092 | 0.26% | $110.07M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 165,689 | 0.21% | $87.23M | 2026-08-03 |
| Renaissance Technologies LLC | ▲ Buy | 109,784 | 0.14% | $57.79M | 2026-08-13 |
| AllianceBernstein L.P. | ▲ Buy | 95,773 | 0.12% | $53.81M | 2026-08-14 |
| Marshall Wace, LLP | ▲ Buy | 93,128 | 0.12% | $49.03M | 2026-08-13 |
| Millennium Management LLC | ▲ Buy | 78,980 | 0.10% | $41.58M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2026-01-13 | 2026-02-02 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-12-02 | 2026-01-05 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-10-29 | 2025-11-04 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-10-16 | 2025-11-04 |
| Byron Donalds | House | FL19 | ▲ Buy | $1K - $15K | 2025-09-04 | 2025-10-07 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-08-07 | 2025-09-02 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-08-01 | 2025-09-02 |
| April McClain Delaney | House | MD06 | ▼ Sell | $1K - $15K | 2025-07-09 | 2025-08-05 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-05-15 | 2025-06-09 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $100K - $250K | 2025-05-12 | 2025-06-22 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-04-09 | 2025-05-02 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-04-28 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-04-07 | 2025-05-02 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $50K - $100K | 2025-04-07 | 2025-05-08 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-04-04 | 2025-05-02 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-04-01 | 2025-05-02 |
| April McClain Delaney | House | MD06 | ▲ Buy | $1K - $15K | 2025-03-14 | 2025-04-02 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-03-13 | 2025-04-11 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-01-22 | 2024-02-14 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2023-04-03 | 2023-05-12 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2022-10-05 | 2022-11-10 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2021-03-29 | 2021-07-23 |